NEOVACS
🏢 View company profile →21Patents
9Active
21Granted
39Portfolio score
Filing activity: Jun 27, 1994 → May 29, 2019 · 6 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6093405A | Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines | Chemistry; Metallurgy | 17 | Expired |
| US7022482B2 | Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses | Chemistry; Metallurgy | 12 | Expired |
| US8697047B2 | Stable immunogenic product comprising antigenic heterocomplexes | Human Necessities | 11 | Active |
| US6455045B1 | Immunogenic compounds with in particular an anti-cytokine effect, preparation process, pharmaceutical compositions and kits containing them | Chemistry; Metallurgy | 9 | Expired |
| US6132721A | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | Emerging Cross-Sectional Technologies | 9 | Expired |
| US6200575A | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6420141B1 | Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids | Emerging Cross-Sectional Technologies | 8 | Expired |
| US7314629B2 | Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus | Chemistry; Metallurgy | 8 | Expired |
| US6878370B1 | Chemically modified TNF-α | Human Necessities | 3 | Expired |
| US7887811B2 | Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein | Human Necessities | 2 | Active |
| US8372388B2 | Method for preparing a stable TNF-α vaccine | Human Necessities | 0 | Active |
| US7351554B2 | Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's | Chemistry; Metallurgy | 0 | Active |
| US9993565B2 | Method for treating IFNalpha related conditions | Chemistry; Metallurgy | 0 | Active |
| US8101165B2 | Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors | Human Necessities | 0 | Active |
| US7022326B1 | Carboxymethylated retroviral regulatory proteins and interferon-α | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7015016B2 | Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's | Chemistry; Metallurgy | 0 | Expired |
| US7504479B2 | Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses | Chemistry; Metallurgy | 0 | Active |
| US6228890A | Use of alicyclic diamines as immunomodulators | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7972603B2 | Stable immunogenic product comprising antigenic heterocomplexes | Human Necessities | 0 | Expired |
| US12059457B2 | Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity | Human Necessities | 0 | Active |
| US8679483B2 | High-yield method for the production of human antibodies blocking the biological activity of a human cytokine | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.